Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Bought by Smartleaf Asset Management LLC

Smartleaf Asset Management LLC raised its position in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 389.3% during the 4th quarter, Holdings Channel reports. The firm owned 10,020 shares of the company’s stock after acquiring an additional 7,972 shares during the quarter. Smartleaf Asset Management LLC’s holdings in Takeda Pharmaceutical were worth $132,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Versant Capital Management Inc acquired a new stake in Takeda Pharmaceutical in the fourth quarter valued at $26,000. Wilmington Savings Fund Society FSB acquired a new stake in Takeda Pharmaceutical in the third quarter valued at $40,000. BNP Paribas Financial Markets grew its holdings in Takeda Pharmaceutical by 416.0% in the third quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock valued at $46,000 after purchasing an additional 2,596 shares during the last quarter. Smithfield Trust Co grew its holdings in Takeda Pharmaceutical by 76.9% in the third quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock valued at $49,000 after purchasing an additional 1,490 shares during the last quarter. Finally, Erste Asset Management GmbH acquired a new stake in shares of Takeda Pharmaceutical during the third quarter valued at $52,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Up 1.2 %

TAK opened at $15.18 on Friday. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. The firm has a market cap of $48.29 billion, a P/E ratio of 37.94, a PEG ratio of 0.24 and a beta of 0.46. Takeda Pharmaceutical Company Limited has a 52 week low of $12.57 and a 52 week high of $15.22. The business’s fifty day simple moving average is $13.59 and its 200 day simple moving average is $13.91.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.42 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. As a group, equities research analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.